Do analysts prefer CAMP or INMB?

CAMP4 Therapeutics currently has a consensus price target of $9.79, suggesting a potential upside of 130.80%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CAMP4 Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CAMP4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer INMB or ALEC?

Alector has a consensus target price of $3.63, suggesting a potential upside of 89.79%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Which has higher valuation & earnings, INMB or ALEC?

INmune Bio has higher earnings, but lower revenue than Alector. INmune Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,293.15 -$45.93M -$0.67 N/A Alector $21.05M 10.13 -$142.93M -$1.10 N/A

Is INMB or ALEC more profitable?

INmune Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. INmune Bio's return on equity of -82.87% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Alector -850.13% -531.03% -44.00%

Does the media favor INMB or ALEC?

In the previous week, Alector had 1 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Alector and 2 mentions for INmune Bio. Alector's average media sentiment score of 0.28 beat INmune Bio's score of 0.00 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INMB or ALXO?

ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 170.59%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 ALX Oncology 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is INMB or ALXO more profitable?

INmune Bio's return on equity of -82.87% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% ALX Oncology N/A -90.30% -67.28%

Do analysts recommend MGNX or INMB?

MacroGenics presently has a consensus price target of $6.33, suggesting a potential upside of 52.98%. Given MacroGenics' higher possible upside, research analysts plainly believe MacroGenics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is MGNX or INMB more profitable?

INmune Bio has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. INmune Bio's return on equity of -82.87% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -8.70% -109.26% -18.70% INmune Bio N/A -82.87% -62.23%

Does the media favor MGNX or INMB?

In the previous week, INmune Bio had 1 more articles in the media than MacroGenics. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for MacroGenics. INmune Bio's average media sentiment score of 0.00 beat MacroGenics' score of -0.23 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ANIK or INMB?

Anika Therapeutics presently has a consensus target price of $22.00, indicating a potential upside of 5.72%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Anika Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer ANIK or INMB?

In the previous week, Anika Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for INmune Bio. Anika Therapeutics' average media sentiment score of 0.80 beat INmune Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

INmune Bio (INMB) Competitors

$2.33 +0.15 (+6.88%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.34 +0.01 (+0.34%)

As of 09/18/2026 07:50 PM Eastern

Compare

INMB vs. CAMP, ALEC, ALXO, MGNX, and ANIK

Should you buy INmune Bio stock or one of its competitors? INmune Bio's main competitors and comparable companies include CAMP4 Therapeutics (CAMP), Alector (ALEC), ALX Oncology (ALXO), MacroGenics (MGNX), and Anika Therapeutics (ANIK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does INmune Bio compare to CAMP4 Therapeutics?

CAMP4 Therapeutics (NASDAQ:CAMP) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

INmune Bio has lower revenue, but higher earnings than CAMP4 Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	76.02	-$80.40M	-$2.32	N/A
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A

CAMP4 Therapeutics currently has a consensus price target of $9.79, suggesting a potential upside of 130.80%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CAMP4 Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

12.7% of INmune Bio shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

INmune Bio has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. INmune Bio's return on equity of -82.87% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
INmune Bio	N/A	-82.87%	-62.23%

In the previous week, INmune Bio had 2 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 2 mentions for INmune Bio and 0 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 0.00 equaled INmune Bio'saverage media sentiment score.

Company	Overall Sentiment
CAMP4 Therapeutics	Neutral
INmune Bio	Neutral

CAMP4 Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Summary

INmune Bio beats CAMP4 Therapeutics on 10 of the 16 factors compared between the two stocks.

How does INmune Bio compare to Alector?

INmune Bio (NASDAQ:INMB) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

INmune Bio has higher earnings, but lower revenue than Alector. INmune Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A
Alector	$21.05M	10.13	-$142.93M	-$1.10	N/A

INmune Bio has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Alector has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

INmune Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. INmune Bio's return on equity of -82.87% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Alector	-850.13%	-531.03%	-44.00%

In the previous week, Alector had 1 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Alector and 2 mentions for INmune Bio. Alector's average media sentiment score of 0.28 beat INmune Bio's score of 0.00 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alector has a consensus target price of $3.63, suggesting a potential upside of 89.79%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

INmune Bio beats Alector on 9 of the 17 factors compared between the two stocks.

How does INmune Bio compare to ALX Oncology?

INmune Bio (NASDAQ:INMB) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

INmune Bio has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 170.59%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

INmune Bio has higher revenue and earnings than ALX Oncology. INmune Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

INmune Bio's return on equity of -82.87% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
ALX Oncology	N/A	-90.30%	-67.28%

In the previous week, INmune Bio had 2 more articles in the media than ALX Oncology. MarketBeat recorded 2 mentions for INmune Bio and 0 mentions for ALX Oncology. INmune Bio's average media sentiment score of 0.00 equaled ALX Oncology'saverage media sentiment score.

Company	Overall Sentiment
INmune Bio	Neutral
ALX Oncology	Neutral

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 12.4% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

INmune Bio beats ALX Oncology on 9 of the 14 factors compared between the two stocks.

How does INmune Bio compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

MacroGenics presently has a consensus price target of $6.33, suggesting a potential upside of 52.98%. Given MacroGenics' higher possible upside, research analysts plainly believe MacroGenics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

INmune Bio has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. INmune Bio's return on equity of -82.87% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
INmune Bio	N/A	-82.87%	-62.23%

In the previous week, INmune Bio had 1 more articles in the media than MacroGenics. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for MacroGenics. INmune Bio's average media sentiment score of 0.00 beat MacroGenics' score of -0.23 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

INmune Bio has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.76	-$74.62M	-$0.22	N/A
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A

MacroGenics has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Summary

INmune Bio beats MacroGenics on 10 of the 17 factors compared between the two stocks.

How does INmune Bio compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Anika Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Anika Therapeutics presently has a consensus target price of $22.00, indicating a potential upside of 5.72%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Anika Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Anika Therapeutics has higher revenue and earnings than INmune Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.47	-$10.88M	-$0.27	N/A
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Anika Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for INmune Bio. Anika Therapeutics' average media sentiment score of 0.80 beat INmune Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

INmune Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
INmune Bio	N/A	-82.87%	-62.23%

Summary

Anika Therapeutics beats INmune Bio on 11 of the 16 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.67M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-3.48	14.23	275.49	25.40
Price / Sales	1,293.15	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	2.65	15.45	10.46	6.33
Net Income	-$45.93M	-$22.86M	$3.49B	$358.33M
7 Day Performance	4.95%	-1.21%	0.59%	1.12%
1 Month Performance	7.87%	-3.29%	-1.74%	-2.39%
1 Year Performance	22.63%	37.74%	18.13%	5.35%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	0.2576 of 5 stars	$2.33 +6.9%	N/A	+22.6%	$64.67M	$50K	N/A	21
CAMP CAMP4 Therapeutics	3.3531 of 5 stars	$4.42 +0.3%	$9.56 +116.2%	+85.2%	$277.67M	$3.50M	N/A	644	Positive News Analyst Upgrade
ALEC Alector	1.9593 of 5 stars	$2.48 +0.6%	$3.63 +46.5%	-37.0%	$277.48M	$21.05M	N/A	270	Gap Down
ALXO ALX Oncology	1.7574 of 5 stars	$2.01 -0.2%	$4.60 +129.4%	+40.5%	$277.25M	N/A	N/A	40	Analyst Upgrade
MGNX MacroGenics	1.7667 of 5 stars	$4.31 -2.1%	$6.33 +47.0%	+155.6%	$273.66M	$149.50M	N/A	430

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. CAMP, ALEC, ALXO, MGNX, and ANIK

How does INmune Bio compare to CAMP4 Therapeutics?

Summary

How does INmune Bio compare to Alector?

Summary

How does INmune Bio compare to ALX Oncology?

Summary

How does INmune Bio compare to MacroGenics?

Summary

How does INmune Bio compare to Anika Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. CAMP, ALEC, ALXO, MGNX, and ANIK

How does INmune Bio compare to CAMP4 Therapeutics?

Which has better earnings & valuation, CAMP or INMB?

Do analysts prefer CAMP or INMB?

Do insiders & institutionals have more ownership in CAMP or INMB?

Is CAMP or INMB more profitable?

Does the media favor CAMP or INMB?

Which has more volatility and risk, CAMP or INMB?

Summary

How does INmune Bio compare to Alector?

Which has higher valuation & earnings, INMB or ALEC?

Which has more volatility & risk, INMB or ALEC?

Is INMB or ALEC more profitable?

Does the media favor INMB or ALEC?

Do analysts prefer INMB or ALEC?

Do insiders and institutionals have more ownership in INMB or ALEC?

Summary

How does INmune Bio compare to ALX Oncology?

Which has more risk & volatility, INMB or ALXO?

Do analysts rate INMB or ALXO?

Which has stronger valuation & earnings, INMB or ALXO?

Is INMB or ALXO more profitable?

Does the media refer more to INMB or ALXO?

Do institutionals & insiders hold more shares of INMB or ALXO?

Summary

How does INmune Bio compare to MacroGenics?

Do analysts recommend MGNX or INMB?

Is MGNX or INMB more profitable?

Does the media favor MGNX or INMB?

Do institutionals and insiders have more ownership in MGNX or INMB?

Which has stronger valuation & earnings, MGNX or INMB?

Which has more risk and volatility, MGNX or INMB?

Summary

How does INmune Bio compare to Anika Therapeutics?

Which has more volatility and risk, ANIK or INMB?

Do analysts recommend ANIK or INMB?

Which has preferable earnings and valuation, ANIK or INMB?

Do institutionals & insiders believe in ANIK or INMB?

Does the media prefer ANIK or INMB?

Is ANIK or INMB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools